Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company's $3.1 billion neuroscience portfolio performance in 2025.
Tag: Xyrem
All
Latest
All
Latest
Xywav Maintains Upward Trajectory in Narcolepsy and Idiopathic Hypersomnia Treatment
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia
All
LatestSorry, No Posts Found
Tris Pharma Is Working on a Low Sodium, Once-Nightly Oxybate Formulation for Narcolepsy
Tris has developed an oxybate formulation intended for the treatment of cataplexy or excessive daytime sleepiness in people with narcolepsy.
Read More
Jazz Updates Xyrem, Xywav Prescription Forms
On February 9, Jazz Pharmaceuticals plc made changes to its XYWAV and XYREM prescription forms to decrease prescriber confusion.
Read More
FDA Grants Orphan Drug Status to Xywav, Citing “Greatly Reduced Chronic Sodium Burden Compared to Xyrem”
The FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read More
What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk
A literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read More
Xywav or Xyrem: What’s the Difference?
The FDA approved a new oxybate formulation for excessive daytime sleepiness or cataplexy in narcolepsy. Should your patients switch?
Read MoreJazz Presents New Data on Xywav & Sunosi at Virtual SLEEP 2020
Highlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read More
FDA Approves Low Sodium Narcolepsy Oral Solution
Marketed by Jazz Pharmaceuticals, Xywav is for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read More
FDA Accepts NDA for Low-Sodium Alternative to Xyrem for Narcolepsy
The FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc’s NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read MoreJazz Pharma’s Sleep Disorder Drug Gets European Panel Backing
Solriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA), according to a statement from the...
Read More